CY1120516T1 - Θεραπειες για τον καρκινο - Google Patents

Θεραπειες για τον καρκινο

Info

Publication number
CY1120516T1
CY1120516T1 CY20181100519T CY181100519T CY1120516T1 CY 1120516 T1 CY1120516 T1 CY 1120516T1 CY 20181100519 T CY20181100519 T CY 20181100519T CY 181100519 T CY181100519 T CY 181100519T CY 1120516 T1 CY1120516 T1 CY 1120516T1
Authority
CY
Cyprus
Prior art keywords
cancer
treatment
nuc
stem cells
cancer stem
Prior art date
Application number
CY20181100519T
Other languages
English (en)
Inventor
Hugh GRIFFITH
Chris Mcguigan
Chris Pepper
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120516(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NuCana plc filed Critical NuCana plc
Publication of CY1120516T1 publication Critical patent/CY1120516T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αναφέρεται στο NUC-1031 ([φαινυλο-βενζοξυ-L-αλανινυλο)]-φωσφορική γεμσιταβίνη), ένα ProTide παράγωγο της γεμσιταβίνης, για χρήση στη στόχευση καρκινικών βλαστοκυττάρων. Η στόχευση αυτή των καρκινικών βλαστοκυττάρων μπορεί να αξιοποιηθεί στην πρόληψη ή θεραπεία του καρκίνου. Η εφεύρεση παρέχει επίσης το NUC-1031 για χρήση στη θεραπεία υποτροπιάζοντος ή ανθεκτικού καρκίνου στον άνθρωπο. Χωρίς να επιθυμείται δέσμευση από οποιαδήποτε υπόθεση, πιστεύεται ότι η ικανότητα του NUC-1031 να στοχεύει καρκινικά βλαστικά κύτταρα συμβάλλει στη χρησιμότητα του στη θεραπεία υποτροπιαζόντων ή ανθεκτικών καρκίνων.
CY20181100519T 2015-05-14 2018-05-18 Θεραπειες για τον καρκινο CY1120516T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (1)

Publication Number Publication Date
CY1120516T1 true CY1120516T1 (el) 2019-07-10

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100519T CY1120516T1 (el) 2015-05-14 2018-05-18 Θεραπειες για τον καρκινο

Country Status (25)

Country Link
US (3) US20180289733A1 (el)
EP (2) EP3197456B2 (el)
JP (1) JP6761852B2 (el)
KR (1) KR20180021697A (el)
CN (2) CN107835687A (el)
AU (2) AU2015394135B2 (el)
BR (1) BR112017024461B1 (el)
CA (1) CA2985540C (el)
CY (1) CY1120516T1 (el)
DK (1) DK3197456T3 (el)
EA (1) EA201792509A1 (el)
ES (1) ES2668377T3 (el)
HR (1) HRP20180762T1 (el)
HU (1) HUE038541T2 (el)
IL (1) IL255591B (el)
LT (1) LT3197456T (el)
MX (2) MX2020009154A (el)
MY (1) MY192081A (el)
PH (1) PH12017502086A1 (el)
PL (1) PL3197456T3 (el)
PT (1) PT3197456T (el)
RS (1) RS57371B1 (el)
SI (1) SI3197456T1 (el)
TR (1) TR201806642T4 (el)
WO (1) WO2016181093A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
MY176133A (en) 2012-11-16 2020-07-24 Nucana Biomed Ltd Process for preparing nucleoside prodrugs
MX2016015629A (es) 2014-06-25 2017-08-02 Nucana Biomed Ltd Formulacion que comprende un profarmaco de gemcitabina.
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
ES2742167T3 (es) 2014-11-28 2020-02-13 NuCana plc Nuevos derivados éster 2' y/o 5' de fosforamidato de aminoácidos de la 3'-desoxiadenosina como compuestos anticancerígenos
BR112018003594A2 (pt) 2015-09-25 2018-09-25 Hoffmann La Roche cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
EA037248B1 (ru) 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
EP3386998B1 (en) 2015-12-11 2021-11-10 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
WO2017109444A1 (en) * 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
SG11201805184TA (en) * 2015-12-23 2018-07-30 NuCana plc Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
EP3863674A2 (en) * 2018-10-12 2021-08-18 The Regents of the University of Colorado, a body corporate Compositions and methods for reducing cancer stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2569215T3 (es) * 2007-09-10 2016-05-09 Boston Biomedical, Inc. Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用

Also Published As

Publication number Publication date
JP2018515618A (ja) 2018-06-14
IL255591A (en) 2018-01-31
HRP20180762T1 (hr) 2018-08-24
TR201806642T4 (tr) 2018-06-21
EP3197456A1 (en) 2017-08-02
US20180289733A1 (en) 2018-10-11
LT3197456T (lt) 2018-07-10
AU2015394135A1 (en) 2017-12-14
CN115837028A (zh) 2023-03-24
BR112017024461B1 (pt) 2023-04-04
US20210100825A1 (en) 2021-04-08
IL255591B (en) 2021-10-31
AU2015394135B2 (en) 2021-09-16
MY192081A (en) 2022-07-26
KR20180021697A (ko) 2018-03-05
AU2021277614A1 (en) 2021-12-23
WO2016181093A1 (en) 2016-11-17
MX2017014544A (es) 2018-09-26
ES2668377T3 (es) 2018-05-17
EP3197456B1 (en) 2018-04-04
CN107835687A (zh) 2018-03-23
DK3197456T3 (en) 2018-06-06
EP3197456B2 (en) 2023-10-11
RS57371B1 (sr) 2018-08-31
CA2985540A1 (en) 2016-11-17
MX2020009154A (es) 2022-03-08
PH12017502086A1 (en) 2018-04-30
JP6761852B2 (ja) 2020-09-30
CA2985540C (en) 2021-08-24
US20230226092A1 (en) 2023-07-20
HUE038541T2 (hu) 2018-10-29
PT3197456T (pt) 2018-05-22
EP3415149A1 (en) 2018-12-19
PL3197456T3 (pl) 2018-09-28
EA201792509A1 (ru) 2018-05-31
BR112017024461A2 (pt) 2018-07-24
SI3197456T1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
CY1120516T1 (el) Θεραπειες για τον καρκινο
EA201691931A1 (ru) 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201690306A1 (ru) Ингибиторы ido
NZ714415A (en) Substituted nucleosides, nucleotides and analogs thereof
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201892803A1 (ru) Противоопухолевая терапия
PH12017501879A1 (en) Methods for treating cancer
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
EP4306173A3 (en) Compositions and methods for treating cancers
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
MX2017013669A (es) Composiciones para el tramiento del cancer.